Neurocrine Biosciences (NASDAQ:NBIX) Receives Hold Rating from Needham & Company LLC

Neurocrine Biosciences (NASDAQ:NBIX)‘s stock had its “hold” rating reiterated by Needham & Company LLC in a report released on Friday,Benzinga reports.

Other research analysts have also issued research reports about the stock. Raymond James reissued an “outperform” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Barclays decreased their target price on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Royal Bank of Canada dropped their price target on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a research report on Friday, October 4th. BMO Capital Markets reduced their price objective on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research report on Thursday, October 17th. Finally, StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 1st. Five research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $166.00.

Neurocrine Biosciences Stock Up 0.3 %

NASDAQ:NBIX opened at $135.42 on Friday. The company’s 50 day moving average is $123.99 and its 200-day moving average is $130.59. Neurocrine Biosciences has a 12 month low of $110.95 and a 12 month high of $157.98. The firm has a market cap of $13.71 billion, a price-to-earnings ratio of 36.31 and a beta of 0.34.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 1,091 shares of the business’s stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total value of $147,285.00. Following the transaction, the insider now owns 2,507 shares of the company’s stock, valued at approximately $338,445. The trade was a 30.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jude Onyia sold 2,331 shares of the firm’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the sale, the insider now owns 15,449 shares of the company’s stock, valued at approximately $1,951,054.21. This trade represents a 13.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.30% of the company’s stock.

Institutional Trading of Neurocrine Biosciences

Several hedge funds have recently modified their holdings of NBIX. Ashton Thomas Private Wealth LLC acquired a new position in Neurocrine Biosciences during the 2nd quarter worth $28,000. Innealta Capital LLC bought a new stake in shares of Neurocrine Biosciences during the second quarter worth $30,000. Blue Trust Inc. lifted its stake in shares of Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after acquiring an additional 220 shares during the period. Plato Investment Management Ltd boosted its holdings in Neurocrine Biosciences by 44.1% in the second quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock valued at $59,000 after acquiring an additional 130 shares during the last quarter. Finally, Truvestments Capital LLC acquired a new stake in Neurocrine Biosciences in the third quarter worth about $63,000. 92.59% of the stock is owned by institutional investors.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.